NPA board member cbdMD hosting invitation-only CBD investor conference
It will be moderated by Lance Blundell, Esq. General Counsel for cbdMD. Owen Bennett from Jefferies, Rupesh Parikh from Oppenheimer & Co, and Ashok Kumar from Think Equity will have a Q&A with Daniel Fabricant, PhD, president and CEO of Natural Products Association.
Photo © AdobeStock.com/Elroi
To help clarify the CBD landscape for investors, the Natural Products Association (NPA; Washington, D.C.) board member cbdMD is hosting an invitation-only virtual investor conference, “Regulatory Roadmap for The CBD Industry,” on Oct. 21, 2020 at 10 a.m. It will be moderated by Lance Blundell, Esq. General Counsel for cbdMD. Owen Bennett from Jefferies, Rupesh Parikh from Oppenheimer & Co, and Ashok Kumar from Think Equity will have a Q&A with Daniel Fabricant, PhD, president and CEO of Natural Products Association (NPA; Washington, D.C.).
NPA has been actively lobbying FDA to regulate CBD since 2017; it has testified on a number of occasions and held several meetings with top FDA officials regarding CBD. NPA also helped craft legislation passed by the U.S. House of Representatives that would have provided resources so FDA can perform a Health Hazard Evaluation and set a safe level of CBD for consumers to use each day.
Invitation-only requests can be made through the sponsors, Jefferies, Oppenheimer & Co, and Think Equity. A transcript of the conference will be made available to the public on Oct. 26, 2020.
FDA revokes authorization to use Red No. 3 as a color additive in food or drugs
January 15th 2025FDA contends that the color additive is safe for humans but is legally obligated by the Delaney Clause of the FD&C act to revoke authorization as research shows the Red No. 3 induces cancer in rats.
